US2017183663A1PendingUtilityA1
Fluorescent fusion polypeptides and methods of use
Est. expiryApr 30, 2030(~3.7 yrs left)· nominal 20-yr term from priority
C12N 15/63C12N 15/62C07K 16/32C07K 16/30C07K 2319/60G01N 33/53G01N 33/582C07K 2317/62A61K 49/0045C07K 2319/00C07K 16/18C07K 2317/622A61K 49/0058A61N 5/062C07K 14/001C12Q 1/04
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus.
Claims
exact text as granted — not AI-modified1 - 18 . (canceled)
19 . A polynucleotide that encodes the polypeptide comprising:
a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus.
20 . A cell comprising the polynucleotide of claim 19 .
21 - 22 . (canceled)
23 . The cell of claim 20 wherein the cell comprises a microbe.
24 . The cell of claim 20 wherein the cell comprises a tumor cell.
25 . A method comprising introducing into a cell a polynucleotide that encodes a polypeptide that comprises:
a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus.
26 . The method of claim 25 wherein the cell comprises a tumor cell.
27 - 51 . (canceled)
52 . A method of making a fusion polypeptide, the method comprising:
creating an expression vector that comprises a polynucleotide operably linked to a promoter, wherein the polynucleotide encodes an fusion polypeptide comprising:
a fluorescent domain comprising a C-terminus and an N-terminus;
a first antibody domain covalently linked to the C-terminus; and
a second antibody domain covalently linked to the N-terminus;
introducing the expression vector into a host cell; and growing the host cell comprising the expression vector in conditions effective for the host cell to express the fusion polypeptide.Join the waitlist — get patent alerts
Track US2017183663A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.